Study S000553

A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3457263 in Healthy Participants and in Patients With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT04641312
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 67
Start: 2020-11-25
Primary completion: 2021-12-21
Lead sponsor: Eli Lilly and Company
Conditions: Healthy; Type 2 Diabetes
Interventions: DRUG:LY3457263; DRUG:Dulaglutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: EUDRACT_NUMBER:2020-001828-34; OTHER:J1R-MC-GZFA

Registered primary outcomes

Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [Baseline through Day 42]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0001412	Nisotirostide (LY3457263), a novel NPY2 receptor agonist for type 2 diabetes and obesity: From discovery to clinical proof of concept. Briere DA, Molecular metabolism	2026	Other trial	PMID 42829171 DOI	cites ClinicalTrials.gov:NCT04641312; registry reference DERIVED:42829171